| UHC UMR Medical and Drug | FDA Cleared or Approved Companion Diagnostic Testing – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Gamifant® (Emapalumab-Lzsg) – Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Gastrointestinal Motility Disorders, Diagnosis and Treatment - Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Gastrointestinal Pathogen Nucleic Acid Detection Panel Testing for Infectious Diarrhea – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Gene Therapies for Hemophilia B – Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Glaucoma Surgical Treatments – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Habilitation and Rehabilitation Therapy (Occupational, Physical, and Speech) – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Home Hemodialysis – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Hospital Services: Observation and Inpatient - Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Hysterectomy – Commercial and Individual Exchange Medical Policy | 2026-01-01 |